Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Cancer vaccines

John T Schiller et al. Cancer Cell. .

Abstract

Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.T.S. and D.R.L. are co-inventors of U.S. goverment-owned patents related to the HPV vaccine technology that were licensed to Merck and GlaxoSmithKline, but these licensed are now expired. I.H.F. is a named inventor on patents relating to HPV prophylactic and therapeutic vaccines; the University of Queensland as employer of I.H.F. receives royalties from the sale of HPV prophylactic vaccines referred to in the article; I.H.F. is a director of a company (Jingang Medcines Australia Pty LTd) involved in developing thearpeutic vaccines for HPV-associated cancers. E.V. has a consulting or advisory role with Janssen Research and Development and Recursion Pharma and has received research support from Janssen Research and Development; note that these financial relations are not connected to the research reported in this manuscript. E.V. is an author of a patent related to this work (PCT/US2022/023,714). H.K.L. is a member of the board of directors and shareholder of Oncosec; is a co-founder of Replicate, a shareholder, and a member of its scientific advisory board; is a founder of Sonokine, and shareholder; and is a co-founder of Trio, and shareholder. P.A.O. received research funding from and has advised Neon; Therapeutics, Bristol Myers Squibb, Merck, CytomX, Pfizer, Novartis, Celldex, Amgen, Array, AstraZeneca/MedImmune, Armo BioSciences, Xencor, Oncorus, Phio, Evaxion, LG Chem, and Roche/Genentech. V.P. B. is an inventor on patent applications related to work on antigen cross-reactivity and neoantigen quality modeling. P.-Y.D. is an inventor on patents related to CAR T cell therapy and vaccines filed by the University of Geneva and has been a consultant for Amal Therapeutics. D.M. is an inventor on patents related to CAR T cell therapy, filed by the University of Pennsylvania and the University of Geneva, and has been a consultant for Limula Therapeutics and MPC Therapeutics. R.H.V. is an inventor on a licensed patent relating to cancer cellular immunotherapy and cancer vaccines; R.H.V. receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody. All other authors declare no competing interests.

Figures

None
John T. Schiller and Douglas R. Lowy National Cancer Institute
None
Ian H. Frazer The University of Queensland
None
Olivera J. Finn University of Pittsburgh School of Medicine
None
Eduardo Vilar The University of Texas MD Anderson Cancer Center
None
H. Kim Lyerly Duke University
None
Sacha Gnjatic Icahn School of Medicine at Mount Sinai
None
Neeha Zaidi Johns Hopkins School of Medicine
None
Patrick A. Ott Dana Farber Cancer Institute
None
Vinod P. Balachandran Memorial Sloan Kettering Cancer Center
None
Pierre-Yves Dietrich and Denis Migliorini University of Geneva and Swiss Cancer Center Léman
None
Robert H. Vonderheide and Susan M. Domchek University of Pennsylvania
See this image and copyright information in PMC

Publication types

MeSH terms

Substances